title: Antihyperglycemic effects of 3-O-methyl-D-chiro-inositol and D-chiro-inositol associated with manganese in streptozotocin diabetic rats.
abstract: The acute effects after administration of 3-O-Methyl-D-Chiro-inositol, D-Chiro-inositol and manganese, components of the pH 2.0 putative mediator of insulin action, on plasma glucose were examined in low dose streptozotocin-treated rats. 3-O-Methyl-D-Chiro-inositol at a bolus dose of 5 mg/kg decreased plasma glucose 6% at 120 min (p < 0.05). A higher bolus dose of 3-O-Methyl-D-Chiro-inositol (15 mg/kg) promoted a more persistent hypoglycemic effect of 22% at 120 min (p < 0.05). Infusion of 8.3 microg/min of manganese chloride lowered plasma glucose by 23% (p < 0.05). 3-O-Methyl-D-Chiro-inositol (15 mg/kg) together with manganese chloride (8.3 microg/min) promoted a reduction of 49% in 120 min (p < 0.05). D-Chiro-inositol at a bolus dose of 5 mg/kg had no effect. A single dose of 15 mg/kg produced a reduction of 21% (p < 0.05) in 120 min. D-Chiro-inositol (15 mg/kg) associated with manganese chloride (8.3 microg/min) decreased elevated plasma glucose 47% (p < 0.05) in 120 min. D-Chiro-inositol coadministered with manganese reduced glucose concentrations during the final 60 min (p < 0.05). 3-O-Methyl-D-Chiro-inositol and D-chiro-inositol are components of the mediator structure. Manganese is also a presumed component of the mediator, having an important role in glucose uptake, insulin release and mediator generation. These compounds have also been identified in the literature as hypoglycemic agents.
authors.affiliation: Clinical Research Unit, Federal University of Ceara/UECe, National Research Council (CNPq), Fortaleza, Brazil. REITOR@IJECE.BR
authors.forename: M C
authors.initials: MC
authors.lastname: Fonteles
authors.forename: M Q
authors.initials: MQ
authors.lastname: Almeida
authors.forename: J
authors.initials: J
authors.lastname: Larner
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002712:Chlorides / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006943:Hyperglycemia / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007294:Inositol / Q000031:analogs & derivatives / Q000494:pharmacology*; D007295:Inositol Phosphates / Q000494:pharmacology*; D008297:Male; D017895:Manganese Compounds / Q000494:pharmacology*; D011134:Polysaccharides / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001786:Blood Glucose; D002712:Chlorides; D007004:Hypoglycemic Agents; D007295:Inositol Phosphates; D017895:Manganese Compounds; D011134:Polysaccharides; C028039:inositol phosphate glycan; D007294:Inositol; C025340:manganese chloride